Screener
Alnylam Pharmaceuticals ALNY Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 8:11 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001178670-26-000062
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Other investing activities | (25,900) | — |
| Net cash used in investing activities | (388,999) | (27,612) |
| Cash flows from financing activities: | ||
| Proceeds from exercise of stock options and other types of equity, net | 46,718 | 130,587 |
| Proceeds from liabilities related to the sale of future royalties and development funding | 12,000 | — |
| Repayment of liabilities related to the sale of future royalties and development funding | (6,752) | (6,825) |
| Other financing activities | (15) | — |
| Net cash provided by financing activities | 51,951 | 123,762 |
Cover / Front Matter
FAQ
- What is Alnylam Pharmaceuticals's stock issuance proceeds?
- Alnylam Pharmaceuticals (ALNY) reported stock issuance proceeds of $33.56M in Q2 2026.
- How has Alnylam Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Alnylam Pharmaceuticals's stock issuance proceeds decreased by 58.7% year-over-year, from $81.22M to $33.56M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.
Ask your AI about Alnylam Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude